Akèy › Myelofibroz › Utah
Etid klinik pou Myelofibroz nan Utah
9 etid pou Myelofibroz ap chèche patisipan nan sit nan Utah.
Vil nan Utah
Tèks ofisyèl etid la (Anglè)
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06661915A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- Huntsman Cancer Institute, Salt Lake City
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT04176198A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
- Huntsman Cancer Institute At University of Utah, Salt Lake City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT07008118Study of INCA036978 in Participants With Myeloproliferative Neoplasms
- Huntsman Cancer Institute, Salt Lake City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT07441694AlloHCT With PegINFa for Myelofibrosis
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 4, 2026 · NCT05535764Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of Utah, Salt Lake City
Ap rekriteFaz 1
Laj 13 ak plis · Tout sèks · Mizajou May 5, 2026 · NCT04771572A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
- Huntsman Cancer Institute, Salt Lake City
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Feb 12, 2026 · NCT05980806SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Salt Lake City
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- University of Utah, Huntsman Cancer Institute, Salt Lake City
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2025 · NCT06479135Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.